Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into nine sections that are reviewed once a year. Each section is assigned one or two Section Editors, leading authorities in the area, who identify the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Jean-Daniel Lelièvre is a Professor of Immunology at the University Paris Est Créteil, France. He heads the Department of Clinical Immunology and Infectious Diseases and an INSERM team dedicated to the study of HIV pathophysiology in Hospital Henri Mondor, Créteil, France. He is in the charge of the clinical core of the VRI consortium of research teams dedicated to HIV vaccine research, and of the WP7 (prophylactic vaccine) of the European consortium on HIV research (EHVA). He also heads a lab team devoted to immunological analysis after vaccination and to the development of DC targeting vaccines.
Prof. Lelièvre is investigator of several clinical trials in the field of immune-based therapies of HIV infection and HIV vaccine. He is also in charge of the work packages of different European projects on HIV and Ebola vaccines. He is a member of the technical committee of vaccines of the French national agency HAS and the Immunization and Vaccine-Related Implementation Research Advisory Committee (IVIR-AC) of the WHO.
Timothy J. Henrich
Timothy J. Henrich is an Associate Professor of Medicine in the Division of Experimental Medicine at the University of California, San Francisco (UCSF), USA. He heads a translational research group focusing on characterizing and targeting persistent HIV reservoirs to achieve long-term HIV remission or functional cure. His laboratory studies the impact of stem cell transplantation and novel immunotherapies on HIV persistence and is engaged in identifying and targeting non-viral markers of HIV infected cells. Dr Henrich is also engaged in projects involving the design and implementation of single-cell bioengineering technologies and PET-based imaging of viral reservoirs.